Blood analysis of patients with chronic joint diseases receiving low dose radiation therapy
Official title: Immunophenotyping From Blood of Patients Suffering From Chronic Degenerating Joint Diseases and Receiving Local Low Dose Radiation Therapy (LDRT)
Run by University of Erlangen-Nürnberg Medical School · NCT02653079 · Data updated 2026-11-12
This study is testing if low dose radiation therapy can help people with chronic joint diseases feel less pain and move better when other treatments haven't worked.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | University of Erlangen-Nürnberg Medical School Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Erlangen, Bavaria) |
| Status | Recruiting |
| Started | June 2016 |
| Main results expected | December 2025 |
| Study ends | December 2026 |
| Registry record updated | February 16, 2023 |
| Trial ID | NCT02653079 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older diagnosed with specific chronic degenerating joint conditions such as painful shoulder syndrome, elbow syndrome, and various forms of arthritis.
✕Probably not a fit
Patients with a history of malignant diseases or those unable to comply with the study protocol may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on patients suffering from chronic degenerating joint diseases who are receiving low dose radiation therapy (LDRT). It aims to assess the effectiveness of LDRT in reducing pain and improving mobility in patients who have not responded well to conventional treatments. Participants will undergo blood draws and complete questionnaires to evaluate their condition and treatment outcomes. The study seeks to gather data on the molecular and cellular responses to LDRT in these patients.
Why it matters
Potential benefit: If successful, this study could provide a new therapeutic option for patients suffering from chronic joint pain, improving their quality of life.
How similar studies have gone: Previous studies have shown promising results with low dose radiation therapy for chronic joint diseases, indicating potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients suffering and diagnosed for: * painful shoulder syndrome (periarthritis humeroscapularis) * painful elbow syndrome (Epicondylopathia humeri) * benign achillodynia * benign calcaneodynia * arthosis (finger- , rhiz-, gon-, and anklearthrosis * arthritis (gon- and anklearthrosis) * Planned local low dose radiation therapy (LDRT) at the Department of Radiation Oncology, Universitätsklinikum Erlangen. * Age at least 18 years Exclusion Criteria: * patients who are suffering or had suffered from any malignant diseases * fertile patients who refuse effective contraception during study treatment * persistent drug and/or alcohol abuse * patients not able or willing to behave according to study protocol * patients in care * patients that are not able to speak German
Where it's running
-
Department of Radiation Oncology, Universitätsklinikum Erlangen
Erlangen, Bavaria, Germany Recruiting
Study contacts
- Principal investigator: Oliver J Ott, MD — Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg
- Study coordinator: Benjamin Frey, PhD
- Email: benjamin.frey@uk-erlangen.de
- Phone: +49 9131 85 44248
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
KITE-363 treatment for relapsed or refractory autoimmune neurologic diseases
This study will test whether KITE-363 is safe and can help people with relapsed or treatment-resistant autoimmune neurologic diseases such as MS, CIDP, and myasthenia gravis.
-
Immunoadsorption treatment for chronic inflammatory demyelinating polyneuropathy
This observational study will try immunoadsorption as a next-step treatment for adults with CIDP who do not respond well to IVIg or methylprednisolone.
-
Empasiprubart for adults with CIDP
This study will test whether IV empasiprubart helps improve symptoms and is safe for adults with CIDP, with an initial 24-week randomized comparison to placebo followed by two years of empasiprubart for all participants.
-
Imeroprubart for adults with CIDP
This study will test whether the monoclonal antibody Imeroprubart helps adults with active CIDP who are already on stable immunoglobulin or corticosteroid treatment.
-
Empasiprubart versus IVIg for treating CIDP in adults
This trial tests whether empasiprubart works as well as IVIg and is safe for adults with CIDP who currently benefit from IVIg.
-
Evaluating DNTH103 for treating chronic inflammatory demyelinating polyneuropathy
This study is testing a new treatment called DNTH103 to see if it can help adults with chronic inflammatory demyelinating polyneuropathy feel better and stay safe.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.